- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04295460
Triple vs. Double Therapy in naïves HIV-Infected Patients (TRIDUNA)
14. august 2020 opdateret af: Luis F. Lopez-Cortes, Hospitales Universitarios Virgen del Rocío
Effectiveness of a Dual Therapy (Dolutegravir + Lamivudine) on Reduction of the Viral Reservoir, Immune Recovery and Immune Activation Compared With a Triple Therapy (Dolutegravir + Tenofovir Alafenamide/Emtricitabine) in Treatment-naïve HIV-Infected Patients
The objective of this study is to clarify whether if starting antiretroviral treatment based on dual therapy (DTG + 3TC) could provide less control of residual HIV replication and, therefore, a detriment on immune activation and inflammation compared to starting with triple therapy, and could worsen the patients' long-term prognosis.
For this purpose, the investigator has designed a randomized clinical trial where will assess the immunological recovery (CD4+/CD8+), immune activation, proliferation, senescence and apoptosis in T lymphocytes CD4+ and CD8+ cells by flow cytometry, the immune activation of monocytes/ macrophages and plasma concentrations of various inflammatory mediators by ELISAS, and the thymic function, the cellular reservoir of HIV and the degree of HIV DNA transcription by digital dropped PCR.
Studieoversigt
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
70
Fase
- Fase 4
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Seville, Spanien, 41013
- Rekruttering
- Hospital Universitario Virgen del Rocio
-
Kontakt:
- Luis F Lopez-Cortes, MD, PhD
- Telefonnummer: 34 - 955013096
- E-mail: lflopez@us.es
-
Ledende efterforsker:
- Luis F Lopez-Cortes, MD, PhD
-
Ledende efterforsker:
- Alicia Gutierrez-Valencia, Pharm D
-
Underforsker:
- Pompeyo Viciana, MD, PhD
-
Underforsker:
- Rosa Ruiz-Valderas, MD, PhD
-
Underforsker:
- Juan R Castillo-Ferrando, MD, PhD
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Treatment-naïve HIV-1-infected patients ≥ 18 years of age.
- Plasma HIV-1 RNA >5000 and <500.000 copies/ml.
- T lymphocyte CD4+ count in peripheral blood >200/μl.
Patients of childbearing age should consent to use a highly effective contraceptive method from 15 days before the time of inclusion of the study until 30 days after the end of it. It is considered a highly effective method:
- Complete abstinence from penile-vaginal intercourse from 2 weeks prior to administration of Investigational Product, throughout the study, and for at least 2 weeks after discontinuation of all study medications;
- Any intrauterine device with published data showing that the expected failure rate is <1% per year (not all intrauterine devices meet this criterion)
- Male partner sterilization confirmed prior to the female subject's entry into the study, and this male is the sole partner for that subject.
- Approved hormonal contraception.
- Any other method with published data showing that the expected failure rate is <1% per year.
- Signed written informed consent prior to inclusion.
Exclusion Criteria:
- Acute HIV infection
- T lymphocyte CD4+ count in peripheral blood ≤ 200/µl
- Active opportunistic infection.
- Pregnancy at inclusion or during the follow-up
- Active hepatitis C and/or B virus co-infection.
- ALT ≥ 5 times the ULN, or ALT ≥ 3xULN and bilirubin ≥ 1.5xULN (with >35% direct bilirubin).
- Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (apart from hyperbilirubinemia or jaundice due to Gilbert's syndrome or asymptomatic gallstones).
- Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh classification.
- Current or past disease that requires the use subsidiary of treatment with corticosteroids, immunomodulatory agents, interferon or chemotherapeutic agents.
- Any laboratory abnormality grade 3 or 4 according to the U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS (Annex 3)
- Concomitant use of drugs with potential major interactions with the prescribed drugs according to the respective full prescribing information.
- Estimated creatinine clearance <50ml/min.
- History or presence of allergy to the study drugs or their components
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Dual Therapy
Dolutegravir plus lamivudine
|
Randomize to naive-treatment HIV-infected patients to receive dual o triple therapy as initial antiretroviral treatment
Andre navne:
|
Aktiv komparator: Triple Therapy
Dolutegravir plus TAF/FTC
|
Randomize to naive-treatment HIV-infected patients to receive dual o triple therapy as initial antiretroviral treatment
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
proviral HIV-DNA
Tidsramme: 48 and 96 weeks
|
Mean changes in proviral HIV-DNA in PBMCs after 48 and 96 weeks of treatment
|
48 and 96 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Immune Recovery
Tidsramme: 48 and 96 weeks
|
Mean changes immune recovery assessed by CD4+/CD8+ T cell ratio.
|
48 and 96 weeks
|
Immune Activation
Tidsramme: 48 and 96 weeks
|
Mean changes immune activation assessed by the expression of HLA-DR and CD38 in both of CD4+ and CD8+ T cells.
|
48 and 96 weeks
|
Monocytes Activation
Tidsramme: 48 and 96 weeks
|
Mean changes monocytes activation (plasma sCD14 and sCD163).
|
48 and 96 weeks
|
Immunosenescense
Tidsramme: 48 and 96 weeks
|
Mean changes expression of markers for recent thymic emigrants (CD31), proliferation (Ki67), dysfunction (PD-1), senescence (CD57), and apoptosis (annexin A) in both CD4+ and CD8+ T cells.
|
48 and 96 weeks
|
Inflammation
Tidsramme: 48 and 96 weeks
|
Mean changes concentration of pro-inflammatory soluble mediator in plasma: TNF-α, IL-1β, IL-6, IP-10, IFN- γ, MIP-1α, MIP-1β, hsPCR y D-dímers.
|
48 and 96 weeks
|
Viral Reservoir
Tidsramme: 48 and 96 weeks
|
Mean changes viral reservoir size, evaluated by proviral HIV-DNA and HIV-RNA in peripheral blood mononuclear cells (PBMC) and CD4+ T cells isolate.
|
48 and 96 weeks
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Semen
Tidsramme: 24 weeks
|
Mean changes of HIV-RNA seminal plasma viral load
|
24 weeks
|
GALT
Tidsramme: 48 weeks
|
Mean changes of viral reservoir assessed as proviral HIV-DNA and HIV-RNA in GALT
|
48 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
10. marts 2020
Primær færdiggørelse (Forventet)
1. januar 2022
Studieafslutning (Forventet)
1. marts 2023
Datoer for studieregistrering
Først indsendt
2. marts 2020
Først indsendt, der opfyldte QC-kriterier
2. marts 2020
Først opslået (Faktiske)
4. marts 2020
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
18. august 2020
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. august 2020
Sidst verificeret
1. august 2020
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- FIS-TAR-01-2019
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med HIV-infektion
-
University of Santiago de CompostelaOsteology FoundationRekruttering
-
Institut PasteurRekruttering
-
Universidad del DesarrolloAfsluttetHealthcare Associated InfectionChile
-
The University of Texas Health Science Center,...EurofinsAfsluttetOdontogen Deep Space Neck InfectionForenede Stater
-
Imelda Hospital, BonheidenAfsluttetHealthcare Associated InfectionBelgien
-
University of PennsylvaniaAfsluttetAntimikrobiel resistensForenede Stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentAfsluttetMenneskelig mikrobiomForenede Stater
-
Universidad Autonoma de Nuevo LeonUkendtSundhedsrelaterede infektioner
-
Centre Hospitalier Universitaire de NīmesRekrutteringÆldre | Healthcare Associated InfectionFrankrig
-
Centre Hospitalier Universitaire, AmiensAfsluttetHealthcare Associated Infection | IglerFrankrig